全文获取类型
收费全文 | 143篇 |
免费 | 3篇 |
国内免费 | 2篇 |
专业分类
儿科学 | 1篇 |
妇产科学 | 2篇 |
基础医学 | 4篇 |
临床医学 | 4篇 |
内科学 | 5篇 |
神经病学 | 10篇 |
特种医学 | 1篇 |
外科学 | 4篇 |
预防医学 | 2篇 |
眼科学 | 115篇 |
出版年
2022年 | 2篇 |
2021年 | 6篇 |
2020年 | 9篇 |
2019年 | 4篇 |
2018年 | 5篇 |
2017年 | 2篇 |
2016年 | 4篇 |
2015年 | 3篇 |
2014年 | 14篇 |
2013年 | 10篇 |
2012年 | 17篇 |
2011年 | 21篇 |
2010年 | 5篇 |
2009年 | 7篇 |
2008年 | 23篇 |
2007年 | 5篇 |
2006年 | 6篇 |
2005年 | 1篇 |
2004年 | 3篇 |
2003年 | 1篇 |
排序方式: 共有148条查询结果,搜索用时 15 毫秒
1.
Borrelli Enrico Grosso Domenico Vella Giovanna Sacconi Riccardo Battista Marco Querques Lea Zucchiatti Ilaria Prascina Francesco Bandello Francesco Querques Giuseppe 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2020,258(12):2621-2628
Graefe's Archive for Clinical and Experimental Ophthalmology - To estimate the impact of delayed care during the coronavirus disease 2019 (COVID-19) pandemic on the outcomes of patients with... 相似文献
2.
3.
4.
Borrelli Enrico Grosso Domenico Vella Giovanna Sacconi Riccardo Querques Lea Zucchiatti Ilaria Prascina Francesco Bandello Francesco Querques Giuseppe 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2020,258(12):2655-2660
Graefe's Archive for Clinical and Experimental Ophthalmology - To quantify the shrinking in outpatient and intravitreal injections’ volumes in a tertiary referral retina unit secondary to... 相似文献
5.
6.
Giuseppe Querques Maria Cecilia Angulo Bocco Gisele Soubrane Eric H Souied 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2008,246(2):319-321
Purpose To describe a young patient with choroidal neovascularization, associated with Stargardt’s disease, who underwent treatment
with intravitreal ranibizumab.
Methods A 26-year-old man with a diagnosis of Stargard’s disease presented at our department for sudden decreased vison in his right
eye (20/800). Upon a complete oplthamologic examination, including fluorescein angiography (FA), indocyanine green angiography
(ICGA) and optical coherence tomography (OCT), the patient was diagnosed with subfoveal CNV of the right eye. Owing to the
subfoveal localization of the CNV, intravitreal ranibizumab injection was performed on this young patient.
Results Three months after the last intravitreal injection of ranibizumab, fundus biomicroscopy, FA, ICGA and OCT revealed the CNV
closure and total resolution of the associated cistoid macular edema and serous retinal detachment, with no recurrence and
no complication from the intravitreal injection of ranibizumab. Visual acuity improved only to 20/400.
Conclusion Intravitreal ranibizumab injection seems to induce total regression of CNV complicating Stargardt’s disease. Further investigations
are required to confirm our results.
The authors have no proprietary interest in the materials used in this study. 相似文献
7.
8.
Luísa S.M. Mendonça Rhianon Perrott-Reynolds Roy Schwartz Haifa A. Madi Nicola Cronbach Isaac Gendelman Alyson Muldrew Finnian Bannon Konstantinos Balaskas Chui Ming Gemmy Cheung Amani Fawzi Daniela Ferrara K. Bailey Freund James Fujimoto Marion R. Munk Giuseppe Querques Ramiro Ribeiro Philip J. Rosenfeld Nadia K. Waheed 《Ophthalmology》2021,128(7):1109-1112
9.
Mariacristina Vecchio Sankar D. Navaneethan David W. Johnson Giuseppe Lucisano Giusi Graziano Marialuisa Querques Valeria Saglimbene Marinella Ruospo Carmen Bonifati Emmanuele A. Jannini Giovanni F.M. Strippoli 《Clinical journal of the American Society of Nephrology》2010,5(6):985-995
Background and objectives: Sexual dysfunction is very common in patients with chronic kidney disease (CKD), but treatment options are limited. The benefits and harms of existing interventions for treatment of sexual dysfunction were assessed in patients with CKD.Design, setting, participants, & measurements: MEDLINE (1966 to December 2008), EMBASE (1980 to December 2008), and the Cochrane Trial Registry (Issue 4 2008) were searched for parallel and crossover randomized and quasi-randomized trials. Treatment effects were summarized as mean differences (MD) or standardized mean difference (SMD) with 95% confidence intervals (CI) using a random effects model.Results: Fourteen trials (328 patients) were included. Phosphodiesterase-5 inhibitors (PDE5i) compared with placebo significantly increased the overall International Index of Erectile Function-5 (IIEF-5) score (three trials, 101 patients, MD 1.81, 95% CI 1.51 to 2.10), all of its individual domains, and the complete 15-item IIEF-5 (two trials, 80 patients, MD 10.64, 95% CI 5.32 to 15.96). End-of-treatment testosterone levels were not significantly increased by addition of zinc to dialysate (two trials, 22 patients, SMD 0.19 ng/dl, 95% CI −2.12 to 2.50), but oral zinc improved end-of-treatment testosterone levels. There was no difference in plasma luteinizing and follicle-stimulating hormone level at the end of the study period with zinc therapy.Conclusions: PDE5i and zinc are promising interventions for treating sexual dysfunction in CKD. Evidence supporting their routine use in CKD patients is limited. There is an unmet need for studying interventions for male and female sexual dysfunction in CKD considering the significant disease burden.Sexual dysfunction is a set of disorders characterized by physical and psychologic changes that result in the inability to perform satisfactory sexual activities. The condition has been found to be significantly more common in men and women with chronic kidney disease (CKD) than in the general population (1). Men with CKD frequently suffer from reduced libido, erectile dysfunction, and difficulty reaching orgasm (2). Approximately 50% of male predialysis CKD patients and 80% of male dialysis patients have erectile dysfunction (3–6). Moreover, the prevalence of erectile dysfunction in male dialysis patients has been found to increase with age (63% <50 years versus 90% ≥50 years) (3). Similar results have been reported in women with CKD, with 55% of female dialysis patients reporting difficulty with sexual arousal (2). Dysmenorrhea, delayed sexual development, impaired vaginal lubrication, dyspareunia, and difficulties in reaching orgasm are also frequently observed (7,8).Multiple factors contribute to the frequent occurrence of sexual dysfunction in CKD patients, including hormonal disturbances (such as hyperprolactinemia, hypogonadism in males, and changes in hypothalamic-pituitary function in women) (9), anemia (10), CKD mineral and bone disorder (4), psychosocial factors (such as depression, anxiety, poor self-esteem, social withdrawal, marital discord, body image issues, fear of disability and death, loss of employment, and financial difficulties) (2,11,12), autonomic neuropathy (13), medications (including antihypertensives, antidepressant, and histamine receptor blockers) (2), and comorbid illness (such as diabetes mellitus, cardiovascular disease, and malnutrition) (2,14). Sexual dysfunction is inversely associated with GFR (7) and is improved after renal transplantation (15,16), suggesting that CKD per se may contribute to sexual dysfunction in these patients (15).Studies have also identified significant associations between sexual dysfunction in CKD patients and depression (8,17), impaired quality of life (8,17,18), and adverse cardiovascular outcomes (19). Effective treatment of sexual dysfunction in CKD patients may therefore potentially lead to improvement in these patient-level outcomes, although a causal link has not been definitively established (18).Therapies that have been used to treat sexual dysfunction include phosphodiesterase-5 inhibitors (PDE5i), intracavernosal injections, intraurethral suppositories, hormonal therapy, mechanical devices, and psychotherapy. Although many clinical trials and reviews have explored the role of these interventions for sexual dysfunction in nonuremic patients (20–24), the effectiveness and safety of these interventions in patients with CKD have not yet been studied thoroughly. Therefore, we aimed to evaluate the benefits and harms associated with various interventions for sexual dysfunction in patients with CKD. 相似文献
10.
Raimondo Forte Giuseppe Querques Lea Querques Nathalie Massamba Valerie Le Tien Eric H. Souied 《Acta ophthalmologica. Supplement》2012,90(4):e281-e287
Purpose: The purpose of this study was to understand clinical significance of near‐infrared reflectance (NIR), blue fundus autofluorescence (FAF) and near‐infrared autofluorescence (NIA) in dry age‐related macular degeneration (AMD), by correlation with fluorescein angiography (FA) and cross‐sectional spectral domain optical coherence tomography (SD OCT). Methods: We evaluated 110 eyes (62 patients, mean age: 64 ± 8 years) diagnosed with dry AMD between January 2010 and December 2010, which underwent NIR (λ = 830 nm), FAF and FA (excitation λ = 488 nm; emission λ > 500 nm), NIA (excitation λ = 787 nm; emission λ > 800 nm), and simultaneous SD OCT scanning using a combined confocal scanning laser ophthalmoscope/SD OCT device (Spectralis HRA + OCT; Heidelberg Engineering, Heidelberg, Germany). Results: Drusen showed variable increased/decreased NIR, FAF, NIA and FA, which corresponded to variable increased/decreased thickness of the retinal pigment epithelium (RPE) and possible presence of subretinal deposits on SD OCT. Geographic atrophy (GA) was present in 43/110 eyes (39.0%) and showed increased NIR and fluorescence (FA), absent FAF and NIA, and loss of RPE on SD OCT. The hyperautofluorescence of the GA margin was never larger in FAF than that in NIA, while in 16.2% of cases, it was larger in NIA than that in FAF and corresponded to mild choroidal hyperreflectivity on SD OCT. Conclusions: Simultaneous recording of SD OCT scans provided ultrastructural data for the evaluation of NIR, FAF, NIA and FA in dry AMD. Near‐infrared autofluorescence might detect earlier than FAF areas of RPE cell loss at the GA margin. 相似文献